Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports

BACKGROUND: In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiyama, Satoshi, Numata, Kazushi, Moriya, Satoshi, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322437/
https://www.ncbi.nlm.nih.gov/pubmed/32607334
http://dx.doi.org/10.12998/wjcc.v8.i12.2574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322437/
https://www.ncbi.nlm.nih.gov/pubmed/32607334
http://dx.doi.org/10.12998/wjcc.v8.i12.2574

Ejemplares similares